Does Treatment with Sodium-Glucose Cotransporter-2 Inhibitors Affect Adherence to International Society Criteria for Diabetic Ketoacidosis in Adult Patients with Type 2 Diabetes? A Retrospective Cohort Analysis

Objective(s). Diabetic ketoacidosis (DKA) is a rare but well-known complication of sodium-glucose transporter inhibitor (SGLT2i) treatment in patients with type 2 diabetes. The physiological effects of SGLT2i are such that hyperglycaemia and ketonuria are no longer reliable diagnostic tools in patie...

Full description

Saved in:
Bibliographic Details
Main Authors: Aongus O’Brolchain, Joshua Maletsky, Ibrahim Mian, Serena Edwards
Format: Article
Language:English
Published: Wiley 2024-01-01
Series:Journal of Diabetes Research
Online Access:http://dx.doi.org/10.1155/2024/1849522
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832559554234155008
author Aongus O’Brolchain
Joshua Maletsky
Ibrahim Mian
Serena Edwards
author_facet Aongus O’Brolchain
Joshua Maletsky
Ibrahim Mian
Serena Edwards
author_sort Aongus O’Brolchain
collection DOAJ
description Objective(s). Diabetic ketoacidosis (DKA) is a rare but well-known complication of sodium-glucose transporter inhibitor (SGLT2i) treatment in patients with type 2 diabetes. The physiological effects of SGLT2i are such that hyperglycaemia and ketonuria are no longer reliable diagnostic tools in patients treated with this class of medication. Diagnostic criteria for DKA varies between major society guidelines. The Joint British Diabetes Society (JBDS) and American Association of Clinical Endocrinology/American College of Endocrinology (AACE/ACE) have recently made changes to their diagnostic criteria to account for the effects of SGTL2i. This study sought to investigate whether treatment with SGLT2i might result in overdiagnosis of DKA and less adherence to the international diagnostic guidelines in hospitalised patients with type 2 diabetes treated with SGLT2i. Additionally, the demographics and clinical characteristics of patients with type 2 diabetes presenting with DKA were compared based on their treatment with SGLT2i at the time of diagnosis. Design. Retrospective observational study. Setting. Inpatients at two teaching hospitals in Queensland, Australia. Primary Outcome Measure(s). The number of patients meeting the Joint British Diabetes Society (JBDS) and American Association of Clinical Endocrinology/American College of Endocrinology (AACE/ACE) diagnostic criteria for DKA. Patients were divided into two groups by treatment with SGLT2i at the time of diagnosis. Participants. Adult patients (>18 years old) with type 2 diabetes diagnosed with DKA from April 2015 to January 2022. Patients without type 2 diabetes were excluded. Results. One hundred and sixty-five patients were included in this study—comprising 94 patients in the SGLT2i cohort and 70 in the non-SGLT2i cohort. A significantly smaller proportion of patients in the SGLT2i vs. non-SGLT2i cohorts met both JBDS (56% vs. 72%, p=0.035) and AACE/ACE (63% vs. 82%, p=0.009) criteria for diagnosis of DKA. Conclusion. Patients with type 2 diabetes treated with SGLT2i may be more likely to be diagnosed with DKA despite not meeting the criteria. Despite recent adjustments to account the physiological effects of SGLT2i, significant variation in criteria between major society guidelines presents ongoing challenges to clinicians. The proportion of patients diagnosed using both JDBS and AACE/ACE were comparable, suggesting a reasonable degree of agreement.
format Article
id doaj-art-55ccbf3ef8ce4c45bca7dd7868cb716a
institution Kabale University
issn 2314-6753
language English
publishDate 2024-01-01
publisher Wiley
record_format Article
series Journal of Diabetes Research
spelling doaj-art-55ccbf3ef8ce4c45bca7dd7868cb716a2025-02-03T01:29:49ZengWileyJournal of Diabetes Research2314-67532024-01-01202410.1155/2024/1849522Does Treatment with Sodium-Glucose Cotransporter-2 Inhibitors Affect Adherence to International Society Criteria for Diabetic Ketoacidosis in Adult Patients with Type 2 Diabetes? A Retrospective Cohort AnalysisAongus O’Brolchain0Joshua Maletsky1Ibrahim Mian2Serena Edwards3Department of MedicineDepartment of MedicineDepartment of MedicineDepartment of MedicineObjective(s). Diabetic ketoacidosis (DKA) is a rare but well-known complication of sodium-glucose transporter inhibitor (SGLT2i) treatment in patients with type 2 diabetes. The physiological effects of SGLT2i are such that hyperglycaemia and ketonuria are no longer reliable diagnostic tools in patients treated with this class of medication. Diagnostic criteria for DKA varies between major society guidelines. The Joint British Diabetes Society (JBDS) and American Association of Clinical Endocrinology/American College of Endocrinology (AACE/ACE) have recently made changes to their diagnostic criteria to account for the effects of SGTL2i. This study sought to investigate whether treatment with SGLT2i might result in overdiagnosis of DKA and less adherence to the international diagnostic guidelines in hospitalised patients with type 2 diabetes treated with SGLT2i. Additionally, the demographics and clinical characteristics of patients with type 2 diabetes presenting with DKA were compared based on their treatment with SGLT2i at the time of diagnosis. Design. Retrospective observational study. Setting. Inpatients at two teaching hospitals in Queensland, Australia. Primary Outcome Measure(s). The number of patients meeting the Joint British Diabetes Society (JBDS) and American Association of Clinical Endocrinology/American College of Endocrinology (AACE/ACE) diagnostic criteria for DKA. Patients were divided into two groups by treatment with SGLT2i at the time of diagnosis. Participants. Adult patients (>18 years old) with type 2 diabetes diagnosed with DKA from April 2015 to January 2022. Patients without type 2 diabetes were excluded. Results. One hundred and sixty-five patients were included in this study—comprising 94 patients in the SGLT2i cohort and 70 in the non-SGLT2i cohort. A significantly smaller proportion of patients in the SGLT2i vs. non-SGLT2i cohorts met both JBDS (56% vs. 72%, p=0.035) and AACE/ACE (63% vs. 82%, p=0.009) criteria for diagnosis of DKA. Conclusion. Patients with type 2 diabetes treated with SGLT2i may be more likely to be diagnosed with DKA despite not meeting the criteria. Despite recent adjustments to account the physiological effects of SGLT2i, significant variation in criteria between major society guidelines presents ongoing challenges to clinicians. The proportion of patients diagnosed using both JDBS and AACE/ACE were comparable, suggesting a reasonable degree of agreement.http://dx.doi.org/10.1155/2024/1849522
spellingShingle Aongus O’Brolchain
Joshua Maletsky
Ibrahim Mian
Serena Edwards
Does Treatment with Sodium-Glucose Cotransporter-2 Inhibitors Affect Adherence to International Society Criteria for Diabetic Ketoacidosis in Adult Patients with Type 2 Diabetes? A Retrospective Cohort Analysis
Journal of Diabetes Research
title Does Treatment with Sodium-Glucose Cotransporter-2 Inhibitors Affect Adherence to International Society Criteria for Diabetic Ketoacidosis in Adult Patients with Type 2 Diabetes? A Retrospective Cohort Analysis
title_full Does Treatment with Sodium-Glucose Cotransporter-2 Inhibitors Affect Adherence to International Society Criteria for Diabetic Ketoacidosis in Adult Patients with Type 2 Diabetes? A Retrospective Cohort Analysis
title_fullStr Does Treatment with Sodium-Glucose Cotransporter-2 Inhibitors Affect Adherence to International Society Criteria for Diabetic Ketoacidosis in Adult Patients with Type 2 Diabetes? A Retrospective Cohort Analysis
title_full_unstemmed Does Treatment with Sodium-Glucose Cotransporter-2 Inhibitors Affect Adherence to International Society Criteria for Diabetic Ketoacidosis in Adult Patients with Type 2 Diabetes? A Retrospective Cohort Analysis
title_short Does Treatment with Sodium-Glucose Cotransporter-2 Inhibitors Affect Adherence to International Society Criteria for Diabetic Ketoacidosis in Adult Patients with Type 2 Diabetes? A Retrospective Cohort Analysis
title_sort does treatment with sodium glucose cotransporter 2 inhibitors affect adherence to international society criteria for diabetic ketoacidosis in adult patients with type 2 diabetes a retrospective cohort analysis
url http://dx.doi.org/10.1155/2024/1849522
work_keys_str_mv AT aongusobrolchain doestreatmentwithsodiumglucosecotransporter2inhibitorsaffectadherencetointernationalsocietycriteriafordiabeticketoacidosisinadultpatientswithtype2diabetesaretrospectivecohortanalysis
AT joshuamaletsky doestreatmentwithsodiumglucosecotransporter2inhibitorsaffectadherencetointernationalsocietycriteriafordiabeticketoacidosisinadultpatientswithtype2diabetesaretrospectivecohortanalysis
AT ibrahimmian doestreatmentwithsodiumglucosecotransporter2inhibitorsaffectadherencetointernationalsocietycriteriafordiabeticketoacidosisinadultpatientswithtype2diabetesaretrospectivecohortanalysis
AT serenaedwards doestreatmentwithsodiumglucosecotransporter2inhibitorsaffectadherencetointernationalsocietycriteriafordiabeticketoacidosisinadultpatientswithtype2diabetesaretrospectivecohortanalysis